AeroEclipse® II Breath Actuated Nebulizer(BAN)

  CONCERNED WITH EXPOSURE TO SECOND-HAND AEROSOLS?

• CDC reports “...influenza viruses can be transmitted through aerosols…aerosol transmission of influenza can be an important mode of transmission, which has obvious implications for pandemic influenza planning…”
  (http://www.cdc.gov/ncidod/eid/ vol12no11/pdfs/06-0426.pdf)
   
• A study on the CDC website reports that nebulizers presented one of the top three risks of patient care activities for nurses developing SARS.
  (http://www.cdc.gov/niosh/npptl/resources/pressrel/announcements/113004wkshp/pdfs/Presentation )

• RTs are more than twice as likely to develop respiratory symptoms when compared to a control group of Physical Therapists. (Respiratory Health Survey of Respiratory Therapists, Dimich-Ward, et al. Chest 2004; 126: 1048-1053)

• “…evidence suggests some RTs are at risk. At issue is an unintended consequence of liquid nebulization…related to passive inhalation of the exhaust of patients’ aerosolized medications.” (Mist-ical Problem—Aerosolized Patient Exhaust May Jeopardize Practitioner Airways ,Advance for Respiratory Care Practitioners, March 24, 2003.)

AEROECLIPSE® II BAN CAN HELP REDUCE YOUR EXPOSURE:

• Monaghan Medical Corporation has responded to this emerging need with theAeroEclipse® II BAN that produces aerosol in response to the patients’ inspiratory flow. This unique nebulizer is specifically designed for low environmental loss. (Mist-ical Problem—Aerosolized Patient Exhaust May Jeopardize Practitioner Airways ,Advance for Respiratory Care Practitioners, March 24, 2003.

• The dosemetric AeroEclipse® provided the largest inhaled drug mass and the lowest loss to the ambient air.* ( Performance Comparison of Nebulizer Designs: Constant-Output , Breath-Enhanced, and Dosemetric. Rau, et al.Respiratory Care, February 2004, Vol 49 No 2, pg 174-179.)

• The findings of a study conclude the AeroEclipse® II BAN delivers far less aerosol to the environment (see chart below). As the AeroEclipse® II BAN delivers aerosol only on patient inspiration, the vast majority of the aerosolized drug goes to the patient and not into the environment. (Breath Actuated AeroEclipse® II Nebulizer: Performance Validation and Comparison to Competitive Products. J. Schmidt and J. Pevler)

For more information or to contact your Monaghan Medical Corporation sales representative visit our website:

www.monaghanmed.com

^{*These studies used the AeroEclipse® Breath Actuated Nebulizer, not the AeroEclipse® II Breath Actuated Nebulizer (BAN) which is currently on the market. The AeroEclipse® BAN and AeroEclipse® II BAN are equivalent in regards to in vitro performance.1}

¹ARE FIRST AND SECOND GENERATION, MECHANICALLY-OPERATED BREATH-ACTUATED NEBULIZERS (BAN) COMPARABLE BASED ON IN VITRO PERFORMANCE? J. Schmidt, J. Pevler, C. Doyle, K. Wiersema, M. Nagel. J. Mitchell; Respiratory Drug Delivery, 2006: 817-819.

™ and ® are trademarks and registered trademarks of Monaghan Medical Corporation or an affiliate of Monaghan Medical Corporation

† trademarks and registered trademarks of the respective companies